EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness

Tomoka Mamori, Maki Tanioka, Kenji Takada, Hirofumi Hamano, Takahiro Tsukioki, Yuko Takahashi, Tsuguo Iwatani, Tadahiko Shien, Shinichi Toyooka

BioDrugs · 2025

DOI: 10.1007/s40259-024-00686-x ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift BioDrugs, 2025. Verfasst von Tomoka Mamori und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, …. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Trastuzumab, Breast Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Celltrion, Okayama University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Despite the global use of trastuzumab biosimilars, concerns remain regarding their efficacy and safety. In particular, when used concurrently with pertuzumab, trastuzumab biosimilars lack extensive real-world data and safety information. Additionally, as cancer drug expenditures continue to rise worldwide, cost savings from biosimilars have become increasingly important. OBJECTIVE: This study aims to assess the safety, efficacy, and cost effectiveness of trastuzumab originators and their biosimilars in real-world clinical settings, focusing on a large patient population. METHODS: The analysis included 31,661 patients with HER2-positive breast cancer from the Medical Data Vision Co., Ltd. database in Japan. Additionally, adverse event reports for the trastuzumab originator and its biosimilars were obtained for 58,799 patients from the World Health Organization's VigiBase, the global adverse event reporting database. RESULTS: No significant differences were observed in heart failure hospitalizations, liver dysfunction, or infusion reaction rates in both the Medical Data Vision Co., Ltd. database and the World Health Organization's VigiBase. In the Medical Data Vision Co., Ltd. database, the addition of pertuzumab did not significantly influence the incidence of adverse events, and the use of biosimilars significantly reduced medical costs, with no significant difference in breast cancer recurrence rates. CONCLUSIONS: By analyzing two large and diverse datasets from multiple perspectives, we obtained reliable results that the trastuzumab originator and its biosimilars have similar safety profiles. The concurrent use of pertuzumab was also found to be safe. The use of biosimilars can lead to cost savings. These findings provide crucial insights for the evaluation and adoption of biosimilars in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsTrastuzumabBreast NeoplasmsAntineoplastic Agents, ImmunologicalHumansFemaleCost-Benefit AnalysisAntibodies, Monoclonal, HumanizedMiddle AgedErb-b2 Receptor Tyrosine KinasesAgedJapanDatabases, FactualAdultTreatment OutcomeCost-Effectiveness Analysis

Substanzen

Biosimilar PharmaceuticalsTrastuzumabAntibodies, Monoclonal, HumanizedErb-b2 Receptor Tyrosine KinasesAntineoplastic Agents, ImmunologicalpertuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Jap…
  • Medical AI Project, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, 700-8558, Japan. tanioka@okayama-u.ac.jp.
  • Medical AI Project, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, 700-8558, Japan.
  • Department of Pharmacy, Okayama University Hospital, Okayama, 700-8558, Japan.

Förderung

  • Celltrion
  • Okayama University

Zitieren

APA

Mamori, T., Tanioka, M., Takada, K., Hamano, H., Tsukioki, T., Takahashi, Y., Iwatani, T., Shien, T., & Toyooka, S. (2025). Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness. BioDrugs. https://doi.org/10.1007/s40259-024-00686-x

Vancouver

Mamori T, Tanioka M, Takada K, Hamano H, Tsukioki T, Takahashi Y, et al. Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness. BioDrugs. 2025. doi:10.1007/s40259-024-00686-x

BibTeX
@article{Mamori2025,
  author = {Mamori, Tomoka and Tanioka, Maki and Takada, Kenji and Hamano, Hirofumi and Tsukioki, Takahiro and Takahashi, Yuko and Iwatani, Tsuguo and Shien, Tadahiko and Toyooka, Shinichi},
  title = {Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness},
  journal = {BioDrugs},
  year = {2025},
  doi = {10.1007/s40259-024-00686-x}
}
Kostenlos starten →